Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
about
Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statementThe artificial pancreas: is it important to understand how the β cell controls blood glucose?Recombinant A22(G)-B31 (R)-human insulin. A22 addition introduces conformational mobility in B chain C-terminusInsulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical ExperienceUse of a food and drug administration-approved type 1 diabetes mellitus simulator to evaluate and optimize a proportional-integral-derivative controller.Closed-loop insulin delivery utilizing pole placement to compensate for delays in subcutaneous insulin deliveryA closed-loop artificial pancreas based on risk management.Probabilistic evolving meal detection and estimation of meal total glucose appearance.Effects of pulsatile subcutaneous injections of insulin lispro on plasma insulin concentration levels.An Achilles' heel in an amyloidogenic protein and its repair: insulin fibrillation and therapeutic designPharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions.Glucose supply and insulin demand dynamics of antidiabetic agents.Insulin aspart: a new rapid-acting insulin analog.Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study.Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus.Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technologyPharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus.Insulin detemir in the treatment of type 1 and type 2 diabetes.Clinical performance of a device that applies local heat to the insulin infusion site: a crossover study.Closed-loop insulin delivery - what lies between where we are and where we are going?Insulin aspart: a review.Premixed insulin treatment for type 2 diabetes: analogue or human?Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence.Insulin use in elderly diabetic patients.Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy.Use of short-acting insulin aspart in managing older people with diabetes.Insulin aspart in diabetic pregnancy: state of the art.Identification of intraday metabolic profiles during closed-loop glucose control in individuals with type 1 diabetes.Glucose clamp algorithms and insulin time-action profiles.Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations.Toward closing the loop: an update on insulin pumps and continuous glucose monitoring systems.Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs.Guidelines for optimal bolus calculator settings in adults.The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences.Evolution of insulin development: focus on key parameters.Translating the research in insulin injection technique: implications for practice.Ultrafast-acting insulins: state of the artInsulin infusion set: the Achilles heel of continuous subcutaneous insulin infusionPost-production protein stability: trouble beyond the cell factory.Pharmacologic treatment of type 2 diabetes: injectable medications.
P2860
Q26745609-D6BFFDA7-BCC6-4B66-B68C-8296A1E3BE40Q26852992-FC688F61-28AF-4648-BCB6-F225B4FD9BB3Q27677388-60AA52F4-2505-4930-984B-5E4A5E661847Q28085428-CA2D14BC-4E66-4D93-A296-DC59D2943D7DQ30416614-8BA1B2B5-7DB0-4C98-910D-FC91A17C8209Q30424297-101C6F14-153D-44BB-B6FE-919E400C3BAAQ30428124-2AF41EBF-0AA9-4478-8483-7E32DB13EA02Q30434936-B460C2EF-4575-420D-8BC0-24D708D9610BQ30439244-F6954688-A3E4-4FA5-8922-9FEE48C4A958Q30494140-E194CDA1-74B0-4435-8F53-0677A8D1FE72Q33571532-2BDE5D8F-AD50-4B24-A264-13E35243D9C6Q33828255-F21C2076-6567-4F90-9285-659018D0AA2FQ34122518-30DC1B2F-F4F3-4F70-BD48-3E83CF15268AQ34351640-6B678141-D2BD-479C-9913-A63858C8AF13Q34805732-D3395392-C916-44F9-B093-3145FA8A623EQ35123446-B907DC1A-EFF4-40A1-BCC7-CD32024D7E9CQ35671873-F4456E7C-F543-494F-82A7-6613EFB15760Q36012958-2034DF91-BC09-4168-90DE-DBC4B5643E54Q36051244-0ED7EEF8-C67A-4130-93AB-A6AD908327F5Q36316740-FD039973-E87D-4682-8749-C1293249E0FCQ36609772-2122E8D5-4612-4877-BAB7-49C16E5636FBQ36909524-8F02C075-B6D7-4168-835C-626E0412CB72Q36947990-BF72AB60-17FE-449B-A22D-4E21C45CE7F6Q37017362-ABC7E8E0-C48C-45E6-A4E3-A1066367922FQ37067084-261B148F-5E24-4838-AEDB-1734F2599353Q37199942-183AEA38-5723-4240-8497-B76BAF47A8EDQ37346167-A7EE8978-A0FE-430B-AC1E-24252E2058CCQ37404470-EE3DD6C2-9D29-4191-91CC-56AC8B037886Q37689907-8A3E18D0-EB15-4E67-B593-353B931EB07DQ37716042-6DDDD759-6DAF-4DB0-8071-CB2991F80405Q37781158-1B5A88E6-6CCB-4FD0-AEB4-DAB283F2AC39Q37802888-A072B3C6-BA44-41F4-B5A8-32C4A39410FFQ37838032-56DEB7BA-8344-4AD4-93E1-6DB9642EE1EDQ37982891-E366C9AD-F8D1-4470-AB4D-8111B563C02AQ38030454-8AF66902-19F3-4AF9-97DE-34EE6525CF8CQ38034911-8D7332DE-9912-40CE-B4BA-1B27EB8A2AC5Q38037727-ED0D8DCF-5524-48E5-9FD5-7543680B3CB9Q38037730-BC0A98FB-99C9-47D5-929B-A500A4BAAEBBQ38264351-B6CFD637-8599-404A-B65B-BE905C04B54FQ38388602-F2CA556A-6C67-4C50-8DA8-911DB132C33B
P2860
Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Insulin aspart (B28 asp-insuli ...... healthy nondiabetic subjects.
@en
type
label
Insulin aspart (B28 asp-insuli ...... healthy nondiabetic subjects.
@en
prefLabel
Insulin aspart (B28 asp-insuli ...... healthy nondiabetic subjects.
@en
P2093
P1433
P1476
Insulin aspart (B28 asp-insuli ...... healthy nondiabetic subjects.
@en
P2093
Beerdsen P
Lindberg FA
Mudaliar SR
P304
P356
10.2337/DIACARE.22.9.1501
P407
P577
1999-09-01T00:00:00Z